Document
IPR2019-00449, No. 1034 Exhibit - Edman I et al, D Routes of Delivery Case Studies 1 Nasal delivery of peptide drugs, Advanced Drug Delivery Reviews, 8 1992 165 177 Edman I (P.T.A.B. Jan....
Hussain et al. 14 have recently evaluated a new aminopeptidase inhibitor, boroleucine, and its effect on the degradation rate of leucine enkephalin in the nasal cavity of rat using an in vitro perfusing method.
Since nasal biopharmaceutical research is currently directed on absorption and bioavailability, we shall describe in more detail the most recently introduced enhancer systems, namely micro- spheres, STDHF and glycyrrhetinic acid derivatives.
23 Pontiroli, A.E., Alberetto, M., Calderara, A., Pajetta, E. and Pozza, G. (1989) Nasal absorption of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents, Eur.
27 Pontiroli, A.E., Alberetto, M., Pajetta, E., Calderara, A. and Gozza, E. (1987) Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects, Diabetes Metab.
28 Aungst, B.J., Rogers, N.J. and Shefter, E. (1988) Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promotor, J. Pharmacol.
Cite Document
IPR2019-00449, No. 1034 Exhibit - Edman I et al, D Routes of Delivery Case Studies 1 Nasal delivery of peptide drugs, Advanced Drug Delivery Reviews, 8 1992 165 177 Edman I (P.T.A.B. Jan. 28, 2019)
+ More Snippets
Document
IPR2019-00449, No. 1038 Exhibit - Bara, US Patent Application Publication No US20060178290, Serial No 10563,967, published August 10, 2006 Bara (P.T.A.B. Jan. 28, 2019)
[0003] Ethanol constitutes a good solubilizing agent for perfuming ingredients, and additionally has the advantage of being inexpensive and of alloWing the formulation of trans parent compositions.
[0005] A ?rst route consists in replacing ethanol With aqueous compositions containing hydrophilic solubilizing agents such as polyethoxylated hydrogenated castor oils.
Moreover, the presence of Water in a large quantity is capable of causing degradation of the perfuming ingredients over time and therefore of adversely affecting the olfactory characteristics of the product.
[0006] Another solution further consisted in providing perfume compositions in Which the ethanol is at least partially replaced by one or more volatile silicones Which are lineariof the polydimethylsiloxane type4or cyclic.
[0007] HoWever, the applicant has noW discovered, sur prisingly, that by choosing a particular combination of silicone compounds not described in the prior art, it Was possible to obtain a perfume composition Whose rate of evaporation is close to that of ethanol and possessing a ?ash point greater than or equal to 00 C., preferably greater than or equal to 10° C. [0008] The subject of the present invention is therefore a perfume composition comprising a mixture of fragrant mate rials in a physiologically acceptable carrier comprising a mixture of polydimethylsiloxanes, characterized in that the said mixture of polydimethylsiloxanes consists of hexam ethyldisiloxane and octamethyltrisiloxane in a hexamethyl disiloxane to octamethyltrisiloxane Weight ratio ranging from 30:70 to 70:30.
Cite Document
IPR2019-00449, No. 1038 Exhibit - Bara, US Patent Application Publication No US20060178290, Serial No 10563,967, published August 10, 2006 Bara (P.T.A.B. Jan. 28, 2019)
+ More Snippets
Document
IPR2019-00449, No. 1037 Exhibit - Colombo, Mucosal Drug Delivery, Nasal, pp 592 605, Vol 2, Encyclopedia of Controlled Drug Delivery Mathiowitz, editor, John Wiley Sons, 1999 Colombo (P.T...
Cite Document
IPR2019-00449, No. 1037 Exhibit - Colombo, Mucosal Drug Delivery, Nasal, pp 592 605, Vol 2, Encyclopedia of Controlled Drug Delivery Mathiowitz, editor, John Wiley Sons, 1999 Colombo (P.T.A.B. Jan. 2
+ More Snippets
Document
IPR2019-00449, No. 1045 Exhibit - Maitani, et al, Design of ocularlacrimal and nasal systems through analysis of drug administration and absorption, Journal of Controlled Release, Volume 49, I...
Cite Document
IPR2019-00449, No. 1045 Exhibit - Maitani, et al, Design of ocularlacrimal and nasal systems through analysis of drug administration and absorption, Journal of Controlled Release, Volume 49, Issues 2
+ More Snippets
Document
IPR2019-00449, No. 1028 Exhibit - Ivaturi et al, Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers, Acta Neurol Scand 2009 Nov1205353 7 doi 1...
Cite Document
IPR2019-00449, No. 1028 Exhibit - Ivaturi et al, Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers, Acta Neurol Scand 2009 Nov1205353 7 doi 101111j1600
+ More Snippets
Document
IPR2019-00449, No. 1039 Exhibit - Behl et al, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Advanced Drug Delivery Reviews 29 1998 89¿¿¿116 Behl (P...
Cite Document
IPR2019-00449, No. 1039 Exhibit - Behl et al, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Advanced Drug Delivery Reviews 29 1998 89¿¿¿116 Behl (P.T.A.B. Ja
+ More Snippets
Document
IPR2019-00449, No. 1036 Exhibit - Deshmukh et al, Lorazepam in the Treatment of Refractory Neonatal Seizures, Am J Dis Child 1986140101042 1044 Deshmukh (P.T.A.B. Jan. 28, 2019)
Cite Document
IPR2019-00449, No. 1036 Exhibit - Deshmukh et al, Lorazepam in the Treatment of Refractory Neonatal Seizures, Am J Dis Child 1986140101042 1044 Deshmukh (P.T.A.B. Jan. 28, 2019)
+ More Snippets
Document
IPR2019-00449, No. 1043 Exhibit - Knoester, et al, Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray A study in healthy volunteers, Br J C...
Cite Document
IPR2019-00449, No. 1043 Exhibit - Knoester, et al, Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray A study in healthy volunteers, Br J Clin Pharmacol
+ More Snippets
Document
IPR2019-00449, No. 1016 Exhibit - Kee et al, US Patent No 5,369,095, Compositions And Method Comprising Substituted Glycosides As Mucus Membrane Permeation Enhancers, issued Novem...
Cite Document
IPR2019-00449, No. 1016 Exhibit - Kee et al, US Patent No 5,369,095, Compositions And Method Comprising Substituted Glycosides As Mucus Membrane Permeation Enhancers, issued November 29, 1994 Kee (P.T
+ More Snippets
Document
IPR2019-00449, No. 1018 Exhibit - Tenta, US Patent No 3,949,072, Seborrheic Keratosis Treatment, issued April 6, 1976 Tenta (P.T.A.B. Jan. 28, 2019)
Cite Document
IPR2019-00449, No. 1018 Exhibit - Tenta, US Patent No 3,949,072, Seborrheic Keratosis Treatment, issued April 6, 1976 Tenta (P.T.A.B. Jan. 28, 2019)
+ More Snippets
Document
IPR2019-00449, No. 1019 Exhibit - Ueda et al, US Patent No 4,657,901, Pharmaceutical Composition, issued April 14, 1987 Ueda (P.T.A.B. Jan. 28, 2019)
Cite Document
IPR2019-00449, No. 1019 Exhibit - Ueda et al, US Patent No 4,657,901, Pharmaceutical Composition, issued April 14, 1987 Ueda (P.T.A.B. Jan. 28, 2019)
+ More Snippets
Document
IPR2019-00449, No. 1017 Exhibit - Cartt et al, WO 2008137960, Nasal Administration Of Benzodiazepines, published November 13, 2008, International filing date May 7, 2008 PCTUS200806296...
Cite Document
IPR2019-00449, No. 1017 Exhibit - Cartt et al, WO 2008137960, Nasal Administration Of Benzodiazepines, published November 13, 2008, International filing date May 7, 2008 PCTUS2008062961 Cartt ¿¿¿960 (
+ More Snippets
Can’t find
a case you think should be here?
Use our supplemental search tool to find
dockets that you may not see here.

Start a Supplemental Search
Our supplemental search tool searches the government's
database directly, ensuring you get complete results.
Note that for flat-rate users, supplemental search on Federal
Courts costs $0.10/search. Non Federal Courts are free. For
pay-as-you-go members, see
our detailed
pricing page.